Cannabidiol for Postoperative Opioid Reduction in Primary Total Knee Arthroplasty
Eligible age
18–80 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this study is to better understand how daily treatment with cannabidiol (CBD) affects the need for opioid pain medication, as well as pain, inflammation and other related symptoms, after knee replacement surgery. The information collected in this study is necessary to help understand whether CBD may be a useful medication before and/or after surgery. The study hypothesis is that CBD exerts opioid-sparing effects through anti-inflammatory, analgesic, and anxiolytic mechanisms.
Sponsor: Chad Brummett
You may qualify if…
- ✓ Willing and able to read, understand, and sign the informed consent (English)
- ✓ Willingness to participate in all study measures and restrictions, including patient-reported outcomes and longitudinal follow-up
- ✓ Scheduled for surgery: primary total knee arthroplasty
- ✓ Primary diagnosis of osteoarthritis of the surgical knee
- ✓ Individuals of reproductive potential must agree to use acceptable birth control (defined in manual of operating procedures). This includes currently practicing an effective form of two types of birth control for women of childbearing potential, which are defined as those, alone or in combination, that result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly from the screening visit until 28 days after the last study drug administration.
- ✓ Participants must also agree not to donate sperm or eggs during study drug administration
- ✓ Ability to take and to swallow the study medication and be willing to adhere to the treatment regimen
- ✓ Agreement to adhere to Lifestyle Considerations (see protocol) throughout study duration
You may not qualify if…
- ✕ Revision or bilateral total knee arthroplasty
- ✕ Individuals receiving or actively applying for worker's compensation or disability and other aspects associated with potential secondary gain (postoperative disability for recovery is permitted)
- ✕ Severe physical impairment or clinically significant illness (e.g., blindness, paraplegia)
- ✕ Co-morbid medical conditions that may significantly impair physical functional status (e.g., current non-skin malignancies, solid organ transplant in the past year)
- ✕ Illicit drug use (other than cannabis). Unreported opioid use would be exclusionary but reported prescribed opioid use is allowed (e.g. patient denies opioid use but is found to be positive on the urine drug screen)
- ✕ Self-reported use of cannabis products within the 7 days prior to starting study drug
- ✕ Self-reported use of cannabis products within the 8-30 days prior to starting study drug AND either a failed drug screen or inability to confirm successful washout (Note - may be rescreened with appropriate wash-out period)
- ✕ High daily preoperative opioid dose
Where it's recruiting
Ann Arbor · Detroit
Source: ClinicalTrials.gov · NCT06234631 · last updated 2026-04-15